Liraglutide API Powder (CAS 204656-20-2) Manufacturer | B2B Lipopeptide Synthesis
Liraglutide API,CAS 204656-20-2,Liraglutide powder manufacturer,GLP-1 receptor agonist,lipopeptide synthesis,Wholesale Liraglutide API supplier,Fmoc-Lys(Pal-g-Glu-OtBu)-OH pre-conjugated synthesis,Boc-His(Trt)-OH racemization prevention,Liraglutide Gly37-
Content
⚠️ B2B Compliance & Identity Notice
Shaanxi Sunrise (Pharma-Sunrise) operates strictly as an upstream B2B chemical manufacturer and advanced peptide synthesis facility. The materials discussed herein, including Liraglutide API Powder (CAS 204656-20-2), are raw pharmaceutical ingredients designed exclusively for qualified R&D laboratories, CDMOs, and industrial formulation engineers. We do not manufacture, package, or distribute finished retail subcutaneous injection pens or dosage forms. Not for direct human consumption. No C-end retail inquiries will be entertained.
The GLP-1 Hype vs. The Surfactant Reality.
The global pharmaceutical landscape is completely saturated with GLP-1 receptor agonist hysteria. Liraglutide (CAS 204656-20-2)—a 31-amino acid lipopeptide brilliantly engineered from the human GLP-1 (7-37) sequence—ignited the modern metabolic revolution for glycemic control and weight management. The clinical pharmacokinetic data is undeniably legendary. The commercial demand is parabolic. But step away from the glossy investor presentations and walk onto the heavy manufacturing floor. The reality hits you immediately. Synthesizing this specific molecule at an industrial scale is a thermodynamic and chromatographic nightmare.
Liraglutide is not a standard linear sequence. It features a critical C16 fatty acid (palmitic acid) attached to the Lysine residue at position 26 via a gamma-glutamyl (γ-Glu) spacer. This modification forces the peptide to form heptameric structures at the injection site and bind to serum albumin, drastically extending its half-life. Biologically, it is perfect. Chemically, it turns the molecule into a literal surfactant—a biological detergent. The global supply chain is currently flooded with opportunistic, low-tier generic peptide factories claiming to possess "high-yield Liraglutide synthesis." They do not. What they are actually shipping to unsuspecting formulation engineers is a crude, aggregated soup of des-lipid fragments, D-Histidine stereoisomers, and massive fibrillar gels. For a CDMO formulation auditor, utilizing substandard Liraglutide API isn't just a misallocation of budget. It is a critical, irrecoverable project failure that will permanently clog your sterile filtration lines and fail ICH stability testing within weeks.
The 7-37 Minefield: Why Generic SPPS Architectures Collapse
Solid-Phase Peptide Synthesis (SPPS) is the undisputed engine for GLP-1 analogs. However, the presence of the massive lipid side-chain, the Arg34 mutation, and the extreme β-sheet folding tendencies of the backbone turn the fundamental physics of the reaction violently against the chemist. This is exactly where the amateurs are separated from the heavy-industry players.
1. The Amateur Orthogonal Trap (Lys26 Conjugation)
Human GLP-1 (7-37) natively contains two Lysine residues: Lys26 and Lys34. The originators mutated Lys34 to Arginine (Arg34) to ensure the palmitic acid attaches only at position 26. In textbook laboratories, chemists utilize orthogonal protection (like an Mtt group) on Lys26. They build the peptide on the resin, carefully wash away the Mtt group with dilute TFA, and then attempt to couple the lipid. In commercial manufacturing, this is a disaster. If the acidity spikes during Mtt removal, the entire peptide is prematurely cleaved from the resin. If the coupling fails due to steric hindrance, you create a massive "des-lipid" Liraglutide impurity. It fails. Why? Because relying on on-resin orthogonal deprotection at scale introduces uncontrollable kinetic variables.
2. The His7 Racemization Nightmare
The absolute N-terminus of Liraglutide is Histidine (His7). This residue is the master key that physically unlocks the GLP-1 receptor. Because it is the final amino acid coupled during a long SPPS cycle, inexperienced chemists often push the reaction hard using standard Fmoc-His(Trt)-OH and strong bases (like piperidine) for final deprotection. This is a fatal chemical error. Histidine is notoriously sensitive to base-catalyzed racemization. Under these conditions, His7 flips its stereochemistry to form a D-His7 diastereomer. A peptide with D-His7 is biologically dead. Standard C18 HPLC columns cannot resolve this isomer. You end up buying a 99% pure powder where a dangerous percentage of the molecules are completely inactive.
3. The C-Terminal Amide Mistake and Fibrillation
Liraglutide is an analog of GLP-1 (7-37), meaning its C-terminus is a free carboxylic acid (Gly37-OH). Unbelievably, many generic labs mistakenly synthesize it on standard Rink Amide resin, yielding Liraglutide-NH2. This entirely alters the isoelectric point of the molecule. Furthermore, the GLP-1 backbone is fiercely hydrophobic. Around residues 16 to 19, the chain collapses inward, forming rigid β-sheets. Once cleaved and dissolved in aqueous HPLC buffers, the lipid tails interact. The molecules self-assemble into massive micelles and fibrillar gels. They streak across the chromatography column, permanently destroying expensive silica resins and making high-yield purification impossible.
The Shaanxi Sunrise Architecture: Forging the 99.5% Baseline
At Shaanxi Sunrise (Pharma-Sunrise), we do not rely on academic textbooks, and we do not tolerate scale-up uncertainties. We rely on brutally rigorous, data-driven chemical engineering. Our proprietary approach to Liraglutide API manufacturing is explicitly designed to pre-emptively dismantle every single steric, stereochemical, and thermodynamic roadblock mentioned above.
To bypass the Mtt orthogonal trap, we deploy advanced building-block engineering. We do not attempt to attach the lipid on the resin. Instead, we utilize a highly purified, pre-conjugated Fmoc-Lys(Palmitoyl-g-Glu-OtBu)-OH single molecule. By coupling this massive complex as one unit during SPPS, we guarantee 100% structural certainty at position 26 and mathematically eliminate the "des-lipid" impurity. For the N-terminus, we completely abandon Fmoc chemistry, utilizing specialized Boc-His(Trt)-OH. By using a Boc-protected N-terminus, we avoid the final basic piperidine step entirely. The His7 is safely deprotected simultaneously during the final acidic TFA cleavage, suppressing racemization to < 0.1%.
Auditor's Metric: Generic Market Standard vs. Sunrise Parameters
The generic market grade settles for 98% purity. That leaves a massive 2% margin for unknown, potentially immunogenic peptide fragments, uncoupled lipids, D-isomers, and aggregated fibrils. In high-end R&D or rigorous pre-clinical CDMO environments, a 2% impurity profile is a catastrophic liability. Below is the unvarnished analytical data comparison that dictates our uncompromising internal release criteria.
| Analytical Parameter | Generic Market Standard | Sunrise Internal Standard |
|---|---|---|
| HPLC Purity (Area %) | ≥98.0% | ≥99.50% (Strictly Enforced) |
| Single Maximum Impurity | ≤1.0% | ≤ 0.15% (Identified via MS/MS) |
| D-His7 Isomer Content | Often > 2.0% (Unresolved) | ≤ 0.10% (Chiral UPLC Verified) |
| Des-Lipid Impurity Limit | Often > 1.0% | Not Detected (Pre-conjugated) |
| TFA (Trifluoroacetic Acid) Limit | Often > 10% (TFA Salt Form) | Acetate Exchange Available (< 1%) |
| Endotoxin Level (LAL Assay) | < 10 EU/mg | < 1 EU/mg |
The Final Mile: Surfactant Lyophilization and Gelation Control
Even if the synthesis and chromatography are utterly flawless, the final isolation phase ruins countless commercial Liraglutide batches. Because Liraglutide acts as a surfactant, attempting to freeze-dry it from a standard aqueous solution results in violent foaming, bumping, and localized phase separation within the lyophilizer. The physical stress of freezing forces the hydrophobic lipid tails together, triggering massive, irreversible fibrillation. You put in a clear solution; you pull out a biologically dead, insoluble gelatinous brick.
At Shaanxi Sunrise, we control the physics of the phase change. We execute deep-freeze lyophilization cycles utilizing precisely calculated tertiary co-solvent systems (incorporating low-percentage organic modifiers like t-butanol) to disrupt micelle formation prior to freezing. We pull the vacuum down at highly controlled thermodynamic ramps, sublimating the solvent while the molecules are physically locked in a monomeric state. The resulting product is a highly porous, instantaneously soluble crystalline powder. Moisture content is locked strictly below 5.0%. No foaming. No gelation. Absolute, verifiable stability when reconstituted in your sterile compounding facility.
Formulation & QA Auditor FAQ (Deep Dive)Q1: How do you verify the sequence to prove it's not the GLP-1(7-36) Amide variant?
This is a fundamental QA check. We utilize HRMS (High-Resolution Mass Spectrometry) to confirm the exact monoisotopic mass of the Gly37-OH free acid terminus. An amide variant would exhibit a mass difference of -1 Da. Furthermore, our exclusive use of CTC resins physically prevents the formation of a C-terminal amide, providing absolute chemical certainty of the correct Liraglutide structure.
Q2: How do you mathematically guarantee the absence of the D-His7 Isomer?
Standard C18 columns cannot resolve the D-His7 diastereomer from the L-His7 target molecule. We utilize specialized chiral stationary phases during our in-process analytical checks. By aggressively suppressing the racemization kinetics during the final coupling step—via our proprietary Boc-His(Trt)-OH chemistry instead of Fmoc—we ensure the D-His7 impurity is consistently mapped and held below the strict 0.10% threshold.
Q3: How do you resolve the chromatographic streaking caused by lipopeptide micelles?
This is the ultimate bottleneck for generic labs. Liraglutide forms massive micelles in standard water/acetonitrile mobile phases, causing peaks to smear across the baseline. We force the peptide into a monomeric state by operating our preparative HPLC columns at elevated temperatures (typically 50°C - 60°C) and introducing highly specific chaotropic salts into the mobile phase. This sharpens the peak and exposes co-eluting impurities for precise removal.
Q4: Does your Liraglutide API come as a standard TFA salt or Acetate salt?
By default, standard SPPS purification yields the TFA salt. However, deeply understanding the cytotoxic nature of TFA in biological formulations and injectable pens, Shaanxi Sunrise offers targeted salt exchange processes. Upon B2B client request, we process the bulk batch through rigorous ion-exchange chromatography to deliver Liraglutide Acetate salt, strictly capping residual TFA at less than 1%.
Q5: What is the endotoxin limit for your bulk peptide powders?
We enforce strict cleanroom protocols, utilize depyrogenated glassware, and execute terminal sterile filtration (0.22 μm) prior to the lyophilization step. Endotoxin levels are routinely tested via the kinetic chromogenic LAL assay. We strictly enforce a limit of < 1 EU/mg.
Q6: How do I prevent fibrillation during my downstream formulation process?
Fibrillation is triggered by physical shear stress, incorrect pH, or air-water interfaces. When you reconstitute our API, you must formulate it at its optimal stability pH (typically exactly pH 8.15 for Liraglutide) using a physiological buffer (like disodium phosphate dihydrate). Avoid excessive mechanical agitation (vortexing) during mixing, and utilize excipients like propylene glycol and specific preservatives (phenol) which thermodynamically stabilize the peptide monomer against beta-sheet aggregation.
Do Not Compromise Your GLP-1 Pipeline with Substandard Peptides.
Shaanxi Sunrise (Pharma-Sunrise) provides verifiable, high-throughput Liraglutide API (CAS 204656-20-2) engineered for the most rigorous global R&D institutions. Demand the analytical data. We have it ready.
REQUEST FULL COA, LC-MS DATA & B2B QUOTE TODAY*Strictly for B2B procurement, qualified researchers, and industrial compounding entities.